Understanding and managing the adverse effects of antiretroviral therapy.
about
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophagesFocus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorsSynthesis, X-ray Analysis, and Biological Evaluation of a New Class of Stereopure Lactam-Based HIV-1 Protease InhibitorsThe root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitorSystematic identification of synergistic drug pairs targeting HIVDiscovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited CohortsHIPdb: a database of experimentally validated HIV inhibiting peptides.Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa.Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activationNew insights into HIV assembly and trafficking.Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen SwitchingThe effects of traumatic stressors and HIV-related trauma symptoms on health and health related quality of life.Body-drug assemblages: theorizing the experience of side effects in the context of HIV treatment."So far it's been choosing which side effects I want or I can deal with": A grounded theory of HIV treatment side effects among people living with HIV.Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study.Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIV.Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses.Multivalent agents containing 1-substituted 2,3,4-trihydroxyphenyl moieties as novel synthetic polyphenols directed against HIV-1.Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds.Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants.Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.Training in Evidence-Based Practices Increases Likelihood to Integrate Different HIV Prevention Services with Substance-Using Clients.Macrocyclic Assembly: A Dive into the Pecking Order and Applied Aspects of Multitalented Metallomacrocycles
P2860
Q21135536-3BD8D86E-29E1-449B-B300-BB7529720068Q26764925-1CE210E0-F941-435F-A88B-8C059EA4806CQ27677537-218E40B9-477E-4AF0-B34A-B10A8F26617BQ28539308-0CBFEBB9-E467-470F-A147-D192E0FAAF72Q30422333-CFE12B27-79B7-4828-B310-C98DC005FF34Q33630579-63BF63F5-FFB9-4B06-8203-F9F309763937Q33907350-04F1FC13-D294-4F25-ABA5-44156438AFB0Q34566584-16929D5E-FFC7-4DEB-AFCF-0E5C1DAD0D90Q34982530-8F72A07B-C6F2-4FD2-B52A-D858764A2EF5Q35147717-F9CD8AFA-2222-424F-83DC-69BA6214D447Q35606616-D87FE2A1-ADA5-4229-87E9-692C177A4E24Q36307738-15DA6574-1420-4399-B1AA-E9E2643DF197Q36472359-E051B9F1-5ACB-4440-9100-AB0FECE810EBQ36777056-D82B477C-5FBC-4F10-B84B-4C90B9B43ED0Q37280882-5FB6ADDE-3693-40BD-9FAD-E70F59DDD198Q37418447-B91A50DB-FD67-4311-A8E3-6040ADCFB973Q37538106-897C9E07-6F72-4F1D-9488-C88A7EEEBC46Q38164839-6AF08C17-30F1-4B53-BD4B-DF1B69A7AD8FQ38597452-245FE98D-EB29-4AAE-9B7D-C11E38AABB5CQ38965589-6D5F2042-F14C-4A7F-8E26-573D969F1FBEQ38985176-78DAF120-1AD3-4598-B903-FFE4599E4666Q39090535-CFF06FF9-6F91-4613-B287-1C095C631547Q39155306-4FD89F9E-4EDC-4878-BCFE-E04E9E276F44Q39885075-738ADB31-D537-4C5F-AB9F-5ABBE18A7885Q41727459-0E33021E-6938-4FAF-9804-F91F040851C1Q43410386-8321D9C6-D040-46CA-83AA-02639935D309Q44641855-11EA9978-240C-4673-8869-96222F53C1F6Q50124348-193B3CA1-E748-438A-AF79-C1C7F7C3BA49Q51746564-858133D1-C4B2-4DFE-9A2B-B557C84577B5Q59043968-192CE7A0-FC11-41F3-B8CF-B7F310C3C712
P2860
Understanding and managing the adverse effects of antiretroviral therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Understanding and managing the adverse effects of antiretroviral therapy.
@en
Understanding and managing the adverse effects of antiretroviral therapy.
@nl
type
label
Understanding and managing the adverse effects of antiretroviral therapy.
@en
Understanding and managing the adverse effects of antiretroviral therapy.
@nl
prefLabel
Understanding and managing the adverse effects of antiretroviral therapy.
@en
Understanding and managing the adverse effects of antiretroviral therapy.
@nl
P1433
P1476
Understanding and managing the adverse effects of antiretroviral therapy.
@en
P2093
Trevor Hawkins
P304
P356
10.1016/J.ANTIVIRAL.2009.10.016
P577
2009-10-24T00:00:00Z